Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results [Yahoo! Finance]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Yahoo! Finance
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating. The adjustment followed an update to the firm's financial model ahead of the ARDX's fourth-quarter results. Additionally, on January 27, Jefferies also raised its price target on Ardelyx, Inc. (NASDAQ:ARDX) to $15 from $8 and maintained a Buy rating. The firm highlighted the company as one of the most underrated biotech launches and underlined sustained execution on Ibsrela in 2026, along with potential upside from IBS-C, new CIC indications, and extended intellectual property. Peak sales are now projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable. Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company focused on developing and commercializing first-in-class gastrointestinal and cardiorenal therapies. Its lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS-C) and ch
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $17.00 price target on the stock.MarketBeat
- Is Ardelyx (ARDX) Pricing Reflect Its Strong Multi Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- How Ardelyx's Phase 3 ACCEL Trial for IBSRELA in CIC Will Impact Ardelyx (ARDX) Investors [Yahoo! Finance]Yahoo! Finance
- First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAGlobeNewswire
ARDX
Earnings
- 10/30/25 - Beat
ARDX
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 4
- 1/26/26 - Form 4
- ARDX's page on the SEC website